U.S. markets closed
  • S&P Futures

    3,697.75
    +27.75 (+0.76%)
     
  • Dow Futures

    29,545.00
    +202.00 (+0.69%)
     
  • Nasdaq Futures

    11,411.50
    +95.25 (+0.84%)
     
  • Russell 2000 Futures

    1,678.30
    +15.80 (+0.95%)
     
  • Crude Oil

    77.29
    +0.58 (+0.76%)
     
  • Gold

    1,639.20
    +5.80 (+0.36%)
     
  • Silver

    18.51
    +0.03 (+0.16%)
     
  • EUR/USD

    0.9630
    +0.0019 (+0.19%)
     
  • 10-Yr Bond

    3.8780
    +0.1810 (+4.90%)
     
  • Vix

    32.26
    +2.34 (+7.82%)
     
  • GBP/USD

    1.0758
    +0.0075 (+0.70%)
     
  • USD/JPY

    144.5080
    -0.1720 (-0.12%)
     
  • BTC-USD

    19,786.03
    +890.07 (+4.71%)
     
  • CMC Crypto 200

    453.50
    +20.40 (+4.71%)
     
  • FTSE 100

    7,020.95
    +2.35 (+0.03%)
     
  • Nikkei 225

    26,617.76
    +186.21 (+0.70%)
     

Why Are Idera Pharmaceuticals Shares Soaring Today

·1 min read
  • Idera Pharmaceuticals Inc (NASDAQ: IDRA) shared positive interim results from its investigator-sponsored Phase 2 trial, INTRIM 1, involving tilsotolimod, Idera's synthetic Toll-like receptor 9 agonist.

  • Based on these results, the trial has been stopped early.

  • The trial included patients with localized, excised melanoma (pathological tumor stage 3-4) with no regional metastases detected and no evidence of distant metastasis.

  • Noting that there were more patients with ulcerated lesions in the placebo arm than in the tilsotolimod arm, topline interim results showed a 70% lower SLN+ rate among patients injected with tilsotolimod as compared to those injected with placebo.

  • The placebo SLN+ rate was in the mid-40%s.

  • Related: Idera Shares Fall After Early Tilsotolimod Data, Seeks Collaborating Partners For TLR9 Agonist.

  • Statistical significance exceeded the pre-specified p-value of 0.008.

  • Adverse reactions included injection site reactions, malaise, fever, and flu-like symptoms.

  • This interim result validates previously reported results from INTRIM 1 that showed immune activation.

  • The trial will continue to relapse-free survival (RFS) and overall survival (OS) at 5 and 10 years after SLN biopsy.

  • Price Action: IDRA shares are up 24.50% at $0.44 on the last check Tuesday.

See more from Benzinga

Don't miss real-time alerts on your stocks - join Benzinga Pro for free! Try the tool that will help you invest smarter, faster, and better.

© 2022 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.